COVID-19 news update: Total active cases at 7,264 in India, 11 new deaths recorded till 8 am on June 16
COVID-19 cases in India, June 16: The total number of active COVID-19 cases in India as of 8 am on June 16 is at 7,264, according to data from the Ministry of Health and Family Welfare's (MoH&FW).
The ministry's daily COVID-19 bulletin showed a 119 new cases across India over the past 24 hours, with Kerala being the most affected, having reported 87 new COVID-19 cases, data showed.
It is followed by Maharashtra (38), Uttar Pradesh (37), Delhi (33), Rajasthan (30), Tamil Nadu (23), Karnataka (18); Gujarat and Haryana (8 each), Punjab (7), Andhra Pradesh (6), Manipur (5); Jharkhand, Madhya Pradesh, and Assam (4 each); Uttarakhand (3), Jammu and Kashmir (2); Sikkim, Telangana, Puducherry and Chhattisgarh (1 each).
The states of Arunachal Pradesh, Chandigarh (Union Territory), Goa, Ladakh (UT), Himachal Pradesh, Odisha, Mizoram, Bihar, and Tripura, did not report new cases over the past 24 hours, as per the data.
Further, the total number of patients discharged since January 2025 is at 13,604 with as many as 689 of these being till June 16. It added that COVID-19 data from West Bengal is still awaited.
According to the ministry bulletin, the COVID-19 death toll in India, since January this year is at 108 so far, with 11 new COVID-19 deaths reported till 8 am on June 10.
Seven deaths were reported in Kerala: one of an 83-year-old man with pneumonia and COVID-19 sepsis;
one of a 33-year-old man with acute pancreatitis and respitory failure;
one of a 60-year-old man with COVID-19 and sepsis;
one of a 63-year-old woman with septic shock and COVID-19;
one of a 85-year-old man with leptospirosis and COVID-19 pneumonia;
one of a 71-year-old woman with acute leukaemia and COVID-19;
one of a 67-year-old woman with COVID-19 pneumonia.
One death was recorded in Chhattisgarh of an 85-year-old man with chronic respiratory failure with active COVID-19; and another one was reported of a 67-year-old man in Delhi, with lung cancer who died of acute respiratory failure due to COVID-19 pneumonia.
Madhya Pradesh and Maharashtra also reported one death each, respectively of a 52-year-old woman with bronchial asthma and new diabetes diagnosis, and one of a 47-year-old man with cirrhosis of the liver.
Overall, since January 2025, Kerala has recorded the highest number of deaths — 35, followed by Maharashtra (28), Delhi (12), Karnataka (11), Tamil Nadu (7), Madhya Pradesh (4); Uttar Pradesh, Punjab, Gujarat, and Rajasthan (2 each); West Bengal, Chhattisgarh, and Jharkhand (1 each).
To bolster readiness, the central government has initiated mock drills across hospitals nationwide, evaluating critical resources such as oxygen supply, ventilators, and essential medicines to handle potential surges efficiently.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
an hour ago
- News18
Woman Dies Of Covid-19 Shortly After Delivery In MP's Jabalpur, 4th Fatality In Over A Week
Last Updated: Chief Medical and Health Officer Sanjay Mishra said the woman had a 3-year history of breathing issues, which worsened her condition and made her more vulnerable to complications A 21-year-old woman from Narayanganj in Madhya Pradesh's Mandla district has died due to COVID-19, marking the fourth such fatality in the state within a week. Similar deaths were recently reported from Indore, Ratlam, and Khargone, prompting serious concern in the state health department. Chief Medical and Health Officer (CMHO) Sanjay Mishra said the woman had been admitted to Jabalpur Medical College for a caesarean section. After the surgery, she experienced a drop in oxygen levels and was shifted to the ICU. She tested positive for COVID-19 and was moved to the Medicine ICU for isolation, where she later died. Mishra added that the woman had a history of breathing difficulties over the past three years, which made her condition more critical. In Jabalpur, 79 COVID tests have been conducted so far, with three individuals testing positive. Among them was an 80-year-old man from Katni, admitted for heart treatment, who has since recovered and been discharged. Another case involved a 32-year-old patient from Madan Mahal, who has also recovered after five days of treatment. The third case was the aforementioned pregnant woman from Narayanganj. Currently, Madhya Pradesh has nearly 200 COVID-19 cases, with 134 active cases and four deaths reported. According to the Indian Council of Medical Research (ICMR), four new variants of COVID-19 have been identified in India: LF.7, XFG, JN.1, and NB.1.8.1 series. The JN.1 variant is the most prevalent, found in more than half of the samples tested, and is known to weaken immunity.
The Hindu
3 hours ago
- The Hindu
Rising cases of COVID-19 bring to fore associated threat of deep vein thrombosis
India has registered a rise in COVID-19 cases beginning from last week of May this year. As of June 16, the country has 7,264 active cases. The World Health Organisation in its recent report (week of May 19 to 25 2025) that SARS-CoV-2 activity was generally low globally, though elevations have been reported in a few countries in Central America and the Caribbean, Tropical South America, South West and Northern Europe, Western Asia, Southern Asia, South-East Asia, and Eastern Asia. While doctors have stressed that there is no need to panic as a majority of the cases are mild and do not require hospitalisation, this spike in cases, has brought to the fore once again, several associated health risks including deep vein thrombosis (DVT) -- both during and after infection. 'This risk of DVT remains elevated even after recovery from Covid-19, with the risk ratio increasing up to 70 days post-infection,'' said Anil Bansal, member, Delhi Medical Association (DMA). The risk is particularly high in the first week after diagnosis. While the risk decreases in subsequent weeks, it remains elevated for several weeks post-infection, he added. Understanding DVT Deep vein thrombosis (DVT) occurs when a clot forms in one of the deep veins of the body. This usually occurs in the leg. DVT can be dangerous, as the blood clot can break free and travel through the bloodstream. If the blood clot gets lodged in the lung and blocks blood flow, it can lead to pulmonary embolism, which can be life threatening. Venous thromboembolism (VTE) occurs with deep vein thrombosis (DVT) and pulmonary embolism (PE). It can result in significant mortality, morbidity, and healthcare costs. Approximately 30% of patients with symptomatic VTE manifest with PE, and others with DVT. The incidence of DVT in India in the general population is about 1.79 per thousand. More than 50% of post-surgical procedure patients are at risk of developing VTE. The prevailing notion that the incidence of VTE in Asians is less than that in the Western population has been disproved by recent reports. Task force report Previously, a taskforce report by the National Academy of Medical Sciences (India), Delhi on Venous Thromboembolism had noted that in view of the ageing population of India and the increasing burden of non-communicable diseases along with infectious diseases affecting healthcare service delivery, there is a dire need to understand the early impact on the incidence and burden of deep venous thrombosis (DVT) and pulmonary embolism (PE) in India. Increasing age, being male, trauma, surgery, prolonged hospitalisation, malignancy, neurologic disease, central venous catheter, prior superficial vein thrombosis, and varicose veins have been identified as some of the major risk factors for developing VTE. In women, oral contraceptive pill use, pregnancy, and hormone replacement therapy are established as independent risk factors. Some of the important risk factors for surgical patients developing VTE are age, type of surgery, length of procedure, and duration of immobilisation. The task force stated that appropriate prevention and management of VTE was vital but in India, lack of trained human resources (healthcare professionals); inadequate laboratory diagnostic support; inadequate availability of pharmaceutical supplies; lack of awareness in the community; need for suitable research along with equitable distribution of facilities for the management of VTE – hamper 100 per cent safety of patients. The Covid-19-DVT link Aabid Amin Bhatt, medical director, Ujala Cygnus Group of Hospitals explained that COVID-19 and its link with a higher chance of VTE, including DVT and PE, is now well established. 'This link comes from the virus's ability to cause a strong inflammatory reaction, often called a cytokine storm, which can disrupt the usual way blood clots. Research has found that patients, particularly those in the hospital with severe COVID-19, have a hypercoagulable state, meaning their blood is more likely to clot. The virus also directly harms the endothelial cells that line blood vessels, which further increases the risk of clots forming,'' said Dr. Bhat. He added that recent research indicates that even after recovery, individuals who had COVID-19 may remain at an elevated risk for thrombotic events for several months. This has prompted ongoing updates to clinical guidelines recommending thromboprophylaxis (blood thinning treatment) during hospitalisation and, in some cases, even post-discharge. The medical community now regards COVID-19 not just as a respiratory illness, but also as a systemic vascular disease with serious implications for blood clotting and cardiovascular health, he said. Severe Covid-19 and vaccines Abhishek Bansal, senior consultant and chief interventional radiologist, Aakash Healthcare said that a very high percentage of patients admitted with severe COVID-19 infections were observed to be affected by this condition. 'This was noted to be primarily because they had been hospitalised in the ICU for extended periods. Any duration of immobilisation or prolonged bed rest was noted to increase the risk of developing DVT or pulmonary embolism,'' he said. Dr. Bansal stressed that COVID-19 vaccines demonstrated that they are highly efficacious in preventing the occurrence of DVT and pulmonary embolism. 'At the same time, some concerns had been raised about the vaccines themselves potentially causing DVT in a few individuals. However, it has been clearly documented that this risk is extremely low—estimated at approximately one in 10 lakh (one million) patients. Even in such rare cases, the condition is generally mild. It has been emphasised that if the individual had instead suffered from an actual COVID-19 infection, the risk of developing DVT or pulmonary embolism would have been substantially higher,'' he said. Treating and tracking 'Anticoagulant medicine have now been added as a standard treatment protocol of Covid-19 and many deaths have been prevented after we established the relationship between the two medical conditions, '' noted. Surinder Kumar Gupta, associate director, pulmonology, Paras Health, Panchkula. Meanwhile, the WHO noted that it is currently tracking several SARS-CoV-2 variants including variants of interest (JN.1) and variants under monitoring (LP.8.1, NB.1.8.1, XEC, KP.3.1.1, KP.3, and LB.1). 'The most prevalent variant, LP.8.1, accounted for 27% of all submitted sequences in the week ending on 25 May 2025 which is a decrease from 32% in the week ending on 27 April 2025. NB.1.8.1 accounted for 21% of all submitted sequences in the week ending on 25 May 2025, a significant increase from 9% in the week ending on 27 April 2025,'' it said in the recently released data. WHO added that during this reporting period, all other variants showed a stable or decreasing trend. 'Available evidence suggests that JN.1, XEC, LP.8.1, and NB.1.8.1 do not pose additional public health risks relative to other currently circulating SARS-CoV-2 variants,'' it said. At the regional level, LP.8.1 decreased in the Americas and the Western Pacific Region, but slightly increased in the European Region. XEC decreased in all regions with sufficient data. NB.1.8.1 increased in the Americas, Europe, and the Western Pacific Region, but decreased in South-East Asia.
&w=3840&q=100)
First Post
3 hours ago
- First Post
Kennedy's vaccine shake-up could leave Trump's America pay the price
US Health Secretary Robert F Kennedy Jr has undone decades of progress in researching and popularising vaccines. Within months, he has ended vaccine research programmes, cut fundings for vaccine outreach efforts, ended vaccine recommendations, and threatened mass-access to affordable vaccines. read more US Secretary of Health Robert F Kennedy Jr promised to make America healthy again, but his actions are laying groundwork for an unhealthy future. With every decision, Kennedy has added to the anti-vaccine sentiment in the United States and made vaccines inaccessible by taking decisions that are not just likely going to increase costs but also affect availability. During his Senate confirmation, Kennedy had said that he supported vaccines, but he has pandered to the anti-vaccine movement that is quite popular among the far-right 'Make America Great Again' movement of US President Donald Trump. He has not just falsely linked vaccines to autism but has also ended the recommendation that pregnant persons and healthy children should get Covid-19 vaccines. STORY CONTINUES BELOW THIS AD Kennedy threatens mass access to vaccines with one move Kennedy has fired all 17 members of the Advisory Committee on Immunization Practices (Acip) of the Centers for Disease Control and Prevention's (CDC) and replaced them with handpicked vaccine skeptics who share his views. For decades, Acip has recommended which vaccines Americans should get and when. Under the Affordable Care Act (ACA), all insurance companies are required to provide all vaccines for free that are recommended by Acip. With vaccine skeptics at the helm, free access to vaccines is no longer assured, meaning that many Americans could see vaccines becomes expensive. 'If we have a system that has been dismantled — one that allowed for open, evidence-based decision-making and that supported transparent and clear dialogue about vaccines — and then we replace it with a process that's driven largely by one person's beliefs, that creates a system that cannot be trusted,' said Helen Chu, one of the ousted Acip member and a professor of infectious disease at the University of Washington School of Medicine, as per The Hill. Once free vaccine mandate from Acip recommendation is no longer there, Covid-19 vaccine could cost up to $150, the measles, mumps, and rubella (MMR) vaccine could cost anywhere between $95 and $280, and the HPV vaccine could cost more than $300. In the coming days, new Acip members are scheduled to hold votes on recommendations for vaccines for Covid-19, meningococcal, HPV, flu, and RSV for adults and maternal and pediatric populations, according to The Hill. Many ways Kennedy is undermining vaccines Kennedy has taken following actions that undermine vaccines: The cancellation of National Institutes of Health (NIH) programmes for the discovery of new vaccines to prevent future pandemics. The end of CDC's advertising campaign for flu vaccines. The cutting of billions of dollars to state health agencies, including for the modernisation of childhood vaccination.
